Twenty nine patients with gliomas were
Gliomas are the most common primary tumours of the nervous system and there is evidence that the genetic mechanisms involved in their pathogenesis are complex. They exhibit various cytogenetic abnormalities, including polyploidy and aneuploidy, but also a tendency to show specific chromosomal loss, particularly for chromosome 10.' It is possible to detect loss of DNA sequences in tumours by assessing the maintenance or loss of heterozygosity (LOH) in tumour DNA compared with that from the patient's blood. This can be most easily demonstrated if genomic DNA from the patient is heterozygous for a given restriction fragment length polymorphism (RFLP), but one allele is missing from tumour DNA. With this approach, which is more sensitive for small chromosomal deletions, it has been shown that LOH for sequences mapping to chromosome 10 is common in glioblastomas.2 8 Losses of chromosome 17 , particularly the short arm, occur in all grades of astrocytomas.9 '4 Other chromosomal regions lost in some adult astrocytomas include 9p, 13q, 19q, and 22q.241' 18 It has been suggested that survival time is better in patients whose gliomas have normal karyotypes on cytogenetic analysis than those with tumours showing clonal abnormalities,'9 but the relation, if any, between prognosis and molecular genetic abnormalities has not been reported. In 
Results
Eighteen patients had grade IV astrocytomas. figure) . LOH for RFLPs mapping to other chromosomes was detected in four tumours. One of these, a grade IV astrocytoma (case 49), had lost heterozygosity for sequences from chromosomes l9p and 22q. The other losses were in the grade III astrocytoma (1p), and two grade IV astrocytomas (case 33; 4p and case 12; 9q). One grade IV tumour (case 11) showed amplification of the gli oncogene,
There were too few patients with low grade tumours in each category of malignancy, or with chromosomal losses, to pelrmit correlation between molecular genetic data and prognosis. In patients with grade IV astrocytomas, table 2 shows the relevant clinical features. Most were treated by radiotherapy, and in many cases adjuvant chemotherapy, after surgery. Only one patient is still alive, 60 months after her operation.
In patients whose tumours showed LOH for chromosomes 10, 17, By contrast with chromosome 10, partial loss of chromosome 17, particularly involving the distal short arm (17pl 1l-pter) is common and occurs in all grades of astrocytoma, as found here. We found LOH for chromosome 17 in eight of 24 (33%) informative astrocytomas within the range of frequencies reported previously, 11-50%.8 ' All three informative grade IV gliomas with LOH for chromosome 17 had also lost sequences from chromosome 10; this combination is known to occur in 25% to 50% of grade IV tumours with LOH for chromosome 10 , and suggests that these tumours may represent a subset that arises through progression from lower grade astrocytomas.89
James and colleagues'I suggested that LOH for chromosome 17 was confined to tumours of astrocytic differentiation, but one benign oligodendroglioma in this series had an interstitial deletion of one copy of 17p (figure). Relatively few molecular genetic data concerning oligodendrogliomas have been reported; James and coworkers studied six oligodendrogliomas but used fewer chromosome 17 probes than in the present study. LOH for 19q sequences has been described in four of seven oligodendrogliomas. 7 The deletions of chromosome 17p seen in astrocytomas often involve the p53 tumour suppressor gene. This gene has been implicated in the pathogenesis of a wide variety of cancers, and mutations of p53 are found in about 30% of diffuse fibrillary astrocytomas, usually accompanied by loss of the other copy of chromosome 17p, which is to be expected given the recessive nature of tumour suppressor genes'4; however, p53 point mutations have been described without loss of the other 17p,12 1421 and some losses of 17p do not involve the p53 locus.'3 The chromosome 17 deletions in six of our tumours may include p53, but one (a grade I astrocytoma) maintained heterozygosity for p53 with LOH for a more distal 17p locus (figure). These 24 The striking finding in this study is the association between LOH and longer postoperative survival, more than twice as long as those without LOH, in patients with high grade gliomas, despite the small numbers. This may well be explained by the tendency for patients whose tumours showed LOH to have higher Karnofsky scores at presentation, although this was not statistically significant. There was no difference in duration of preoperative symptoms. There was a correlation between Kamofsky status and survival in this series of grade IV tumours overall, as has been noted previously.25 Although age is known to be a major determinant of survival in patients with malignant gliomas2526 and was inversely correlated with survival in this series, there was no difference in age between the two groups of patients defined by presence or absence of LOH. One possible explanation for longer survival in the LOH group is that slightly, but not significantly, more had postoperative radiotherapy, and often adjuvant chemotherapy, than in those without LOH. This was largely determined by Karnofsky status.
The explanation for this finding is not clear. It is unexpected, given recent observations made by von Deimling and colleagues.8 Based on a series of 67 patients with glioblastomas, these authors suggested that two main genetic types could be defined. One showed LOH for chromosome 17 and sometimes for chromosome 10, but did not exhibit amplification of the epidermal growth factor receptor (EGFR) gene. These tumours, which may be derived from lower grade astrocytomas, tended to occur in younger female patients. Amplification of EGFR was only found in tumours with LOH for chromosome 10, but not all of them, and rarely in those with additional LOH for chromosome 17. Patients with this second type of tumour exhibiting EGFR amplification were, on average, older and more likely to be male. Given that age is a major determinant of prognosis in glioblastoma, it might be expected that patients with tumours showing LOH for chromosome 10 would have a particularly poor prognosis. Von Deimling and coworkers8 did not analyse demographic data from their patients without LOH for chromosomes 10 or 17, who had a particularly bad prognosis in our series, although the age range of these patients, like ours, was wide. Our findings, which need to be confirmed, suggest that there is a subset of high grade gliomas, with currently no known molecular genetic substrate, which is particularly aggressive.
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